Valuation: GeNeuro SA

Capitalization 2.31M 2.72M 2.15M 2M 3.74M 250M 3.96M 24.52M 9.73M 118M 10.2M 10M 429M P/E ratio 2022
-2.94x
P/E ratio 2023 -1.84x
Enterprise value 14.15M 16.64M 13.12M 12.26M 22.85M 1.53B 24.22M 150M 59.52M 722M 62.4M 61.13M 2.63B EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
51.41%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
1 week-4.35%
Current month-1.91%
1 month+23.20%
3 months-16.30%
6 months+6.94%
Current year-1.91%
More quotes
1 week 0.03
Extreme 0.0278
0.03
1 month 0.02
Extreme 0.0232
0.04
Current year 0.03
Extreme 0.0262
0.03
1 year 0.02
Extreme 0.0198
0.24
3 years 0.02
Extreme 0.0198
3.48
5 years 0.02
Extreme 0.0198
6.28
10 years 0.02
Extreme 0.0198
13.72
More quotes
Manager TitleAgeSince
Chief Executive Officer 64 2005-12-31
Chief Tech/Sci/R&D Officer 68 2005-12-31
Director of Finance/CFO 64 2015-10-31
Director TitleAgeSince
Chairman 64 2006-02-05
Director/Board Member 83 2008-07-15
Director/Board Member 74 2015-07-20
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
0.00%-4.35%-81.05%-97.84% 1.07M
+0.04%-0.68%-6.02%+14.33% 49.48B
-1.56%-1.00%+15.16%+4.22% 40.07B
+0.15%+0.33%+52.79%+27.21% 37.55B
+1.92%+1.44%+22.35%+42.46% 31.67B
-0.99%-2.20%+186.97%+320.56% 22.74B
-3.01%-3.74%+70.91%+152.23% 16.56B
Average -0.49%-0.10%+37.30%+66.17% 28.3B
Weighted average by Cap. -0.34%-0.28%+42.54%+65.91%
See all sector performances

Financials

2022 2023
Net sales - -
Net income -12.2M -14.34M -11.31M -10.57M -19.7M -1.32B -20.88M -129M -51.31M -622M -53.79M -52.69M -2.26B -14.76M -17.35M -13.68M -12.78M -23.83M -1.59B -25.26M -156M -62.06M -753M -65.06M -63.73M -2.74B
Net Debt 1.53M 1.79M 1.41M 1.32M 2.46M 165M 2.61M 16.17M 6.42M 77.85M 6.73M 6.59M 283M 11.84M 13.92M 10.97M 10.25M 19.12M 1.28B 20.26M 125M 49.79M 604M 52.2M 51.13M 2.2B
More financial data * Estimated data
Logo GeNeuro SA
GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.
Employees
17
More about the company
Date Price Change Volume
26-01-23 0.0308 0.00% 0
26-01-22 0.0308 -0.65% 67,716
26-01-21 0.0310 -0.64% 34,635
26-01-20 0.0312 +4.00% 32,131
26-01-19 0.0300 -6.83% 20,375

Real-time Euronext Paris, January 23, 2026 at 11:55 am EST

More quotes

Annual profits - Rate of surprise